immunotherapy
Finn RS, Kudo M, Barnes G, Meyer T, Boisserie F, Abdrashitov R, Chen Y, Li S, Zhu AX, Qin S, Vogel A. Tislelizumab versus Sorafenib[...]
Naing A, Khalil D, Rosen O, Camidge DR, Lillie T, Ji RR, Stacey A, Thomas M, Rosen L. First-in-human clinical outcomes with NG-350A, an anti-CD40[...]
Yu J, Yang Y, Gu Z, Shi M, La Cava A, Liu A. CAR immunotherapy in autoimmune diseases: promises and challenges. Front Immunol. 2024 Oct[...]
Chow F, Lamoureux F, Moriceau G. Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer. Front Immunol. 2024 Sep 26;15:1487952. doi: 10.3389/fimmu.2024.1487952. PMID: 39391312; PMCID: PMC11464455.
Mi Z, Wang Z, Wang Y, Xue X, Liao X, Wang C, Sun L, Lin Y, Wang J, Guo D, Liu T, Liu J, Modlin[...]
Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud[...]
Lee JM. Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non-small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing. J[...]
Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein[...]
Bakaloudi DR, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary JB, Patgunarajah U, Thomas VM, Swami U, Agarwal N, Jindal T, Koshkin VS, Brown[...]
Evans LK, Chen H, Taki Labib M, Cronkite DA, Yu AC, Ashendouek M, Elashoff D, Chai-Ho W, Wong DJ, St John M. Improved Survival of[...]